MARKET

NTHI

NTHI

NeOnc Technologies Holdings Inc
NASDAQ
3.150
-0.330
-9.48%
After Hours: 3.228 +0.078 +2.47% 17:07 11/20 EST
OPEN
3.460
PREV CLOSE
3.480
HIGH
3.560
LOW
3.100
VOLUME
225.11K
TURNOVER
--
52 WEEK HIGH
11.38
52 WEEK LOW
2.501
MARKET CAP
90.88M
P/E (TTM)
-1.4749
1D
5D
1M
3M
1Y
5Y
1D
NeOnc Technologies Holdings Says FDA Reschedules End-Of-Phase 1 Meeting For Oral NEO212 To November 23
Benzinga · 1d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 1d ago
NeOnc Reports Improved Interim NEO100 Phase 2a Response Rate
TipRanks · 2d ago
Roth MKM Reaffirms Their Buy Rating on NeOnc Technologies Holdings, Inc. (NTHI)
TipRanks · 2d ago
NeOnc Technologies reports updated interim results from NEO100-01 study
TipRanks · 3d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 3d ago
Weekly Report: what happened at NTHI last week (1109-1113)?
Weekly Report · 4d ago
NeOnc Technologies Reports FDA End-of-Phase Meeting for NEO100
TipRanks · 11/13 22:32
More
About NTHI
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. It is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is developing novel drug delivery methods to be used in combination with novel drug candidates. The Company has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).

Webull offers Neonc Technologies Holdings Inc stock information, including NASDAQ: NTHI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTHI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NTHI stock methods without spending real money on the virtual paper trading platform.